Lenalidomide decreased the PSA level for castration‐resistant prostate cancer: a case report

Lenalidomide has been developed as the derivative of thalidomide that has fewer side effects. We herein report a rare case of castration‐resistant prostate cancer successfully maintained using lenalidomide for multiple myeloma.

• Publication year

  2018

• Venue

  Clinical Case Reports

• Publication date

  2018-01-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ccr3.1328PMID 29445483PMCID 5799614
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lenalidomide decreased the PSA level for castration‐resistant prostate cancer: a case report

  2018cited by this paper
• Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.

  2015cited by this paper
• Prostate‐specific antigen‐based prostate cancer screening: Past and future

  2015cited by this paper
• Phase II trial of granulocyte-macrophage colony-stimulating factor plus thalidomide in older patients with castration-resistant prostate cancer.

  2015cited by this paper
• Docetaxel and Prednisone with or without Lenalidomide in Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer ( MAINSAIL ) : A Randomised , Double-Blind , Placebo-Controlled Phase 3 Trial

  2015cited by this paper
• Low‐dose maintenance gemcitabine‐carboplatin chemotherapy could be an alternative to continuous standard chemotherapy for patients with metastatic urothelial carcinoma

  2014cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.

  2010cited by this paper
• An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer

  2003cited by this paper
• Increased Frequency of Venous Thromboembolism with the Combination of Docetaxel and Thalidomide in Patients with Metastatic Androgen‐Independent Prostate Cancer

  2003cited by this paper
• Thalidomide and its analogues inhibit lipopolysaccharide-mediated Iinduction of cyclooxygenase-2.

  2001cited by this paper
• A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.

  2001cited by this paper
• A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.

  2001cited by this paper
• Antitumor activity of thalidomide in refractory multiple myeloma.

  1999cited by this paper
• Management of hormone refractory prostate cancer: current standards and future prospects.

  1998cited by this paper
• Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm.

  1997cited by this paper
• About the authors

  1995cited by this paper
• Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

  1993cited by this paper

• Combination Therapy of Oncolytic Newcastle Virus and Lenalidomide Enhanced Cytotoxicity in Prostate Cancer Cells

  2024cites this paper
• Screening of Drug Repositioning Candidates for Castration Resistant Prostate Cancer

  2019cites this paper
• Lenalidomide decreased the PSA level for castration‐resistant prostate cancer: a case report

  2018cites this paper